MetAlert (OTC: MLRT), a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, was featured on a recent episode of the Stock Day Podcast. MetAlert’s CEO Patrick Bertagna joined Stock Day host Everett Jolly to discuss the company’s background, current projects and focus. “We have expanded the capabilities of our SmartSole(R) platform. We have added Bluetooth, WI-FI and sensors inside of the hardware platform, which will allow us to monitor not just where someone is but also how they are doing… We are also going to be adding products that monitor how people are doing at home… On the R&D side, we’re going to be implementing the new wearables and incorporating them into our hardware platform,” Bertagna said in the interview. “We are very focused on what we call the longevity revolution. We want to be a major player in providing solutions to enable people to live a higher quality life, while extending their lives… We’re going to be looking at potentially making some acquisitions by the second or third quarter of next year, as we gear up to ultimately do an up list to Nasdaq.”
To view the full press release, visit https://ibn.fm/TwLAr
About MetAlert Inc.
MetAlert, a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, is supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. The company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. Utilizing the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technology, MetAlert products enable subscribers to track in real time the whereabouts of people or high-value assets. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible, wearable, technology-tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism or traumatic brain injury. MetAlert’s business model is built around technology innovation and holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in more than 40 countries and is a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about the company, visit www.MetAlert.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
